Zelira Therapeutics Ltd has released a press release.
ZLD Successfully Completes $8.75M Oversubscribed Placement
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
Story so far
Earlier from Zelira Therapeutics
- June 2020 Quarterly Report
- Zelira Enters Deal to Develop Products For Vascular Diseases
- Zelira Phase 1 Chronic Pain Trial Meets Clinical Endpoints
- TasAlk to Manufacture Zeliras Insomnia and HOPE products
- March 2020 Quarterly Report
Later from Zelira Therapeutics
- HOPE Range Of Products Launches In Louisiana
- Appendix 4E & Financial Statements
- Zelira Forms Subsidiary to Launch Oral Care Products in USA
- Zenivol launches in Australia after TGA approves release
- Thorney Becomes a Substantial Strategic Investor in Zelira
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics